NCT06111014

Continuation Study for Latozinemab

A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Alector Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Detailed description

This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study. All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w).

Conditions

• Neurodegenerative Diseases

Interventions

Type	Name	Description
DRUG	Latozinemab	All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks

Timeline

• Start date: 2023-12-08
• Primary completion: 2025-09-01
• Completion: 2026-01-07
• First posted: 2023-11-01
• Last updated: 2026-01-21

Locations

18 sites across 10 countries: United States, Belgium, Canada, France, Germany, Italy, Netherlands, Portugal, Sweden, United Kingdom

Regulatory

• FDA-regulated drug study